Anticipated therapies and not-so-anticipated dominate July PBAC agenda

At its July meeting, the Pharmaceutical Benefits Advisory Committee will consider new therapies for Alzheimer's disease, ovarian cancer, and cystic fibrosis, and a range of biosimilars, generics and new forms of already listed medicines. …